Mischel’s research published in a series of papers in Nature and Science, has catalyzed a paradigm shift in precision oncology that promises to transform the diagnosis and treatment of patients suffering from some of the most aggressive forms of cancer.

In 2021, he joined Stanford University School of Medicine, where he currently serves as a Professor and Vice Chair of Research for the Department of Pathology and Institute Scholar of ChEM-H. Mischel leads the team of eDyNAmiC project.

Studies he has led, published in a series of papers in Nature and Science, has provided a mechanistic understanding of the molecular basis of intratumoral genetic heterogeneity, accelerated evolution and treatment resistance driven by ecDNA oncogene amplification.

His team’s research has shown that ecDNA occurs in close to 20% of all solid cancers, of women and men, children and adults, that it is associated with poor outcome for patients.

[3][4][5][6][7][8][9][10][11][12][13][14] Mischel is a member of the National Academy of Medicine[15] and recipient of the Ernst W. Bertner Memorial Award from MD Anderson for Distinguished Contributions to Cancer Research.